RTP Mobile Logo
Breast Cancer Update, Issue 4, 2010
Released December 2010

Featuring interviews with Drs Charles E Geyer Jr, Kathy D Miller, C Kent Osborne and Matthew J Ellis. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Breast cancer is one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing clinical trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic/prognostic tools. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Appraise the potential utility of genomic assays to aid in the quantification of risk and the selection of individualized treatment for patients with node-negative or node-positive breast cancer.
    • Communicate the efficacy and safety of various chemotherapy regimens in combination with bevacizumab to patients with HER2-negative metastatic breast cancer who may be eligible for anti-angiogenic treatment.
    • Recount the role of poly(ADP-ribose) polymerase (PARP) in the DNA repair pathway, and review the efficacy and safety of the PARP inhibitors for women with triple-negative breast cancer.
    • Consider the efficacy and tolerability of novel agents for the later-line treatment of metastatic breast cancer.
    • Compare and contrast the efficacy, safety and individualized utility of anthracycline- and nonanthracycline-based chemotherapy regimens.
    • Define the role of sentinel lymph node resection versus conventional axillary lymph node dissection in early breast cancer.
    • Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue
     
    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDrs Geyer and Osborne had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr MillerAdvisory Committee: Genentech BioOncology, MethylGene Inc, Roche Laboratories Inc; Speakers Bureau: Genentech BioOncology, Roche Laboratories Inc. Dr EllisAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Merck and Company Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc.

    EDITOR
    Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech BioOncology, Genomic Health Inc and Sanofi-Aventis.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2010
    Expiration date: December 2011

Acknowledge and close

Breast Cancer Update, Issue 4, 2010
Released December 2010

Featuring interviews with Drs Charles E Geyer Jr, Kathy D Miller, C Kent Osborne and Matthew J Ellis. (Text and Audio Content)